| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:238.)
© 2007 American Heart Association, Inc.
Advances in Stroke 2006 |
From the Max Planck Institute for Neurological Research (W.D.H.), Cologne, Germany; and the Massachusetts General Hospital and Harvard Medical School (A.G.S.), Boston, Mass.
Correspondence to A. Gregory Sorensen, MD, Massachusetts General Hospital, 2301 Bldg 149, 13th St, Boston, Mass 02129. E-mail sorensen@nmr.mgh.harvard.edu
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Imaging in stroke continues to be one of the most dynamic fields of stroke research. Over the past year, researchers have used imaging for acute stroke diagnosis, treatment, and management; to assist in the evaluation of new therapies; to gain insight into neurorecovery, to investigate genetic links; and to better understand animal models of stroke. A full range of imaging technologies are being deployed in the fight against stroke: near-infrared optical, magnetic resonance, positron emission tomography (PET), ultrasound, and x-ray CT are all in active use, aided by both routine and novel tracers and contrast agents. A complete overview of all these advances is not possible in the space allotted here. Hopefully, the sampling of the advances over the past year provided here will convey some of the excitement and activity present in this field.
Imaging is often used to first diagnose both ischemic and hemorrhagic stroke, and advances continue to be made in these areas. The long-standing concept of the ischemic penumbra continues to be confirmed by PET, MRI, and CT. Two multicenter studies published in 2006 demonstrated the potential of imaging to identify candidate patients. In DEDAS,1 the MRI diffusion/perfusion mismatch identified patients in the 3- to 9-hour time window for treatment with the thrombolytic desmoteplase, with apparent benefit especially in patients who fulfilled all MRI criteria. In the DEFUSE study,2 MRI was used successfully to identify both patient subgroups likely to benefit and subgroups unlikely to benefit or possibly to be harmed from treatment in the 3-
Related Articles:
Stroke 2007 38: 395-397.
Stroke 2007 38: 216-218.
Stroke 2007 38: 232-234.
Stroke 2007 38: 222-224.
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |